SCHEMBL6580396

SCHEMBL6580396

CCCCC(=O)c1c(-c2ccc3c(-c4ccc(C(F)(F)F)cc4)c(OCC(=O)O)ccc3c2)oc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.45
PTGDR2 Q9Y5Y4 5/20 0.43
ANO1 Q5XXA6 1/20 0.40
PSEN1 P49768 2/20 0.39
ALOX5 P09917 1/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
PPARD Q03181 5/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
PPARA Q07869 2/20 0.38
PPARG P37231 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6579740 0.93 PTPN1 (0.46) PTPN1ANO1ALDH1A1THRATHRB
SCHEMBL6580209 0.92 KDM4E (0.40) PTPN1PTGDR2ANO1PSEN1ALOX5
SCHEMBL6581848 0.89 ANO1 (0.38) PTPN1ANO1PSEN1ALOX5PPARG
SCHEMBL6583890 0.85 PTPN1 (0.47) PTPN1ALDH1A1THRATHRBLMNA
SCHEMBL6583841 0.85 PSEN1 (0.37) PTPN1ANO1PSEN1ALOX5PPARG
SCHEMBL6582342 0.85 KDM4E (0.43) PTPN1ALDH1A1POLBLMNAHTT
SCHEMBL6585755 0.84 PTPN1 (0.48) PTPN1ANO1ALDH1A1THRATHRB
SCHEMBL6581487 0.84 PTPN1 (0.58) PTPN1ANO1ALDH1A1THRATHRB
SCHEMBL6580117 0.84 PTPN1 (0.46) PTPN1ANO1ALDH1A1THRATHRB
SCHEMBL6579760 0.82 LMNA (0.39) PTPN1ANO1ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP claimed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US claimed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US claimed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO claimed
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP disclosed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US disclosed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US disclosed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) F2R, SERPINE1, SERPINC1 PTPN1 1287/4885PTGDR2 1557/4885ANO1 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.